诺诚健华:奥布替尼新适应症在中国上市申请获得批准

人民财讯
25 Apr

  人民财讯4月25日电,诺诚健华(688428)4月25日晚间公告,收到国家药品监督管理局(NMPA)核准签发的《药品注册证书》,奥布替尼(商品名:宜诺凯®)用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(以下简称“CLL/SLL”)的新适应症上市申请获得批准。

(文章来源:人民财讯)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10